Cosentyx (secukinumab) is a medication used to treat several autoimmune and inflammatory conditions by targeting and blocking interleukin-17A (IL-17A), a protein that plays a key role in immune-mediated inflammation[3].
Cosentyx is prescribed for the following indications:
- Moderate to severe plaque psoriasis in adults and children 6 years and older who are candidates for systemic therapy or phototherapy[1][3][5].
- Psoriatic arthritis (PsA) in adults and children 2 years and older, either alone or in combination with methotrexate, particularly when previous disease-modifying antirheumatic drug (DMARD) therapy has been inadequate[1][3][5][6].
- Ankylosing spondylitis (AS), also called radiographic axial spondyloarthritis, in adults with active disease who have responded inadequately to conventional therapy[1][3][5].
- Non-radiographic axial spondyloarthritis (nr-axSpA) in adults with objective signs of inflammation, who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)[1][3][5].
- Enthesitis-related arthritis (ERA), a form of juvenile idiopathic arthritis, in children from 4 years (or 6 years in Europe) and older who have responded inadequately to or cannot tolerate conventional therapy[1][3][5][7].
- Juvenile psoriatic arthritis (JPsA) in patients 6 years and older who have responded inadequately to or cannot tolerate conventional therapy[1].
- Hidradenitis suppurativa (HS), also known as acne inversa, which is a chronic skin disease causing painful lumps and abscesses, in adults with moderate-to-severe active disease when conventional systemic treatments do not work well enough[1][3][5][7].